Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inhibrx Biosciences Inc (NQ: INBX )

14.08 +0.10 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54,884
Open 14.08
Bid (Size) 14.50 (2)
Ask (Size) 15.48 (10)
Prev. Close 13.98
Today's Range 13.87 - 14.28
52wk Range 10.80 - 39.79
Shares Outstanding 37,892,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying
Via Benzinga
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
Via Benzinga

Performance

YTD
-62.99%
-62.99%
1 Month
-10.89%
-10.89%
3 Month
+8.39%
+8.39%
6 Month
-58.82%
-58.82%
1 Year
-31.45%
-31.45%

More News

Read More
INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
Via InvestorPlace
INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024
Via InvestorPlace
Top 4 Health Care Stocks That Are Preparing To Pump This Month
Via Benzinga
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
From Kahn Swick & Foti, LLC
Via Business Wire
JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
Via Benzinga
The NVDA Earnings Effect And What It Means For The Current Market Momentum
Via Talk Markets
Topics Stocks
Exposures US Equities
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
Via Talk Markets
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
From Kahn Swick & Foti, LLC
Via Business Wire
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
Via Investor's Business Daily
Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
Via Benzinga
Why Is Inhibrx (INBX) Stock Soaring 45% Today?
Via InvestorPlace
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
Via Benzinga
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
Via Benzinga
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
Via Investor's Business Daily
Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
Via Benzinga
$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
Via Benzinga
Stocks Reverse Gains After ADP Report
Via Talk Markets
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Via FinancialNewsMedia
Topics Death
Exposures Death
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.